CT-011, a monoclonal PD-1 blocking antibody, enhances natural killer cell activation and cytotoxicity against multiple myeloma

被引：0
|
作者：
Benson, Don
Chandler, Jason
Mishra, Anjali
Baiocchi, Robert
Yu, Jianhua
Liu, Tom
Lozanski, Gerard
Porcu, Pierluigi
Devine, Steven
Rotem-Yehudar, Rinat
Caligiuri, Michael
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Curetech, Yavne, Israel
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5655
引用
收藏
页数：1
相关论文
共 50 条
  • [11] First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma
    Efebera, Yvonne A.
    Rosko, Ashley E.
    Hofmeister, Craig
    Benner, Joe
    Bakan, Courtney
    Stamper, Kathleen
    Lamb, Tammy
    Hollie, Devine
    Sell, Megan
    Avigan, David
    Benson, Don M.
    BLOOD, 2015, 126 (23)
  • [12] PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells
    Guo, Yanan
    Feng, Xiaoli
    Jiang, Yang
    Shi, Xiaoyun
    Xing, Xiangling
    Liu, Xiaoli
    Li, Nailin
    Fadeel, Bengt
    Zheng, Chengyun
    ONCOTARGET, 2016, 7 (30) : 48360 - 48374
  • [13] Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody
    Chu, Fuliang
    Westin, Jason R.
    Zhang, Min
    Feng, Lei
    Baladandayuthapani, Veerabhadran
    Wang, Zhiqiang
    Allen, Rochelle
    Wallace, Michael
    Vence, Luis
    Radvanyi, Laszlo
    Kwak, Larry W.
    Rotem-Yehudar, Rinat
    Davis, R. Eric
    Neelapu, Sattva S.
    BLOOD, 2012, 120 (21)
  • [14] NATURAL-KILLER ACTIVITY AND ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY IN MULTIPLE-MYELOMA
    MATSUZAKI, H
    KAGIMOTO, T
    ODA, T
    KAWANO, F
    TAKATSUKI, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1985, 15 (04) : 611 - 617
  • [15] Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma
    Westin, Jason R.
    Chu, Fuliang
    Fayad, Luis E.
    Kwak, Larry W.
    Fowler, Nathan H.
    Romaguera, Jorge E.
    Hagemeister, F. B.
    Fanale, Michelle
    Samaniego, Felipe
    Allen, Rochelle
    Feng, Lei
    Baladandayuthapani, Veerabhadran
    Rotem-Yehudar, Rinat
    Neelapu, Sattva
    BLOOD, 2012, 120 (21)
  • [16] Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma
    Westin, J. R.
    Chu, F.
    Foglietta, M.
    Rotem-Yehudar, R.
    Neelapu, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [17] PD-L1/PD-1 axis serves an important role in natural killer cell-induced cytotoxicity in osteosarcoma
    Zhang, Ming-Lei
    Chen, Li
    Li, Yan-Jiao
    Kong, Da-Liang
    ONCOLOGY REPORTS, 2019, 42 (05) : 2049 - 2056
  • [18] The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer Cell Cytotoxicity Against Melanoma Cell Lines In Vitro
    Dupuis, Maria L.
    Fiori, Valentina
    Soriani, Alessandra
    Ricci, Biancamaria
    Dominici, Sabrina
    Moricoli, Diego
    Ascione, Alessandro
    Santoni, Angela
    Magnani, Mauro
    Cianfriglia, Maurizio
    JOURNAL OF IMMUNOTHERAPY, 2015, 38 (09) : 357 - 370
  • [19] Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
    Nakamura, Ayano
    Suzuki, Susumu
    Kanasugi, Jo
    Ejiri, Masayuki
    Hanamura, Ichiro
    Ueda, Ryuzo
    Seto, Masao
    Takami, Akiyoshi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [20] Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition
    Favreau, Meredis
    Venken, Koen
    Faict, Sylvia
    Maes, Ken
    De Veirman, Kim
    De Bruyne, Elke
    Leleu, Xavier
    Boon, Louis
    Elewaut, Dirk
    Vanderkerken, Karin
    Menu, Eline
    HAEMATOLOGICA, 2017, 102 (07) : E266 - E270
12345